Glenmark Pharma. Q2 FY27 Results (NSE: GLENMARK)

· Analysis by Alpha Inflection

Signal: Revenue declined

Glenmark Pharma. Q2 FY27 key financials
MetricValueYoYQoQ
Revenue₹4,247.33 Cr-29.8%+5.7%
Net profit₹263.83 Cr-42.6%
EPS₹9.35-56.8%
EBIT marginN/A

P&L walk

Consolidated revenue fell to ₹42,473.28 million, -29.8% YoY and +5.7% QoQ, while gross margin compressed to 69.3% from 79.1% YoY; operating profit before exceptional items fell to ₹6,221.63 million and the ₹2,838.75 million legal settlement reduced PAT to ₹2,638.30 million.

View original filing

Research and educational content only. Not investment advice.